ITCI intracellulartherapies.com Stock Quotes

Intra-Cellular Therapies (ITCI) is implementing software robots for clinic data analysis and testing automated molecule screening. This price action chart, where the indicator equals 131.74, complements the business overview. Intra-Cellular Therapies (ITCI) generates revenue from the sale of prescription drugs for bipolar disorders and schizophrenia. Meanwhile, production is fully outsourced to US contractors, which ensures uninterrupted supplies to pharmacy chains through redundant capacities.

ITCI - Intra-Cellular Therapies Stock Quotes over the range 07/04/2022 - 04/13/2025

Intra-Cellular (ITCI) - metric breakdowns and financial figures

- stock quotes and analyst forecast:

Stock Price Intra-Cellular Therapies|ITCI - Analyst Median Target

- market capitalization data:

Market Valuation Intra-Cellular Therapies Inc.|ITCI - Aggregate Business Value

- issuer book value statistics:

Book Value per Share Intra-Cellular Therapies|ITCI - Company Net Assets|Market Capitalization to Book Value Ratio intracellulartherapies.com|ITCI - Company Total Asset Base

- debt and solvency information:

- earnings and market ratios statistics:

ITCI - Company Net Income|Projected Future Earnings Intra-Cellular Therapies|ITCI - Business Payback Period|Future Price to Earnings Intra-Cellular Therapies|ITCI - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Intra-Cellular Therapies Inc.|ITCI - Company profit before taxes, interest and amortization|Earnings per share for the last twelve months Intra-Cellular Therapies|ITCI - Earnings per share for the trailing year|Quarterly EPS earnings growth intracellulartherapies.com|ITCI - Earnings growth in current year|Expected earnings per share growth for next year Intra-Cellular Therapies

- total revenue and sales volume data:

ITCI - Company Total Sales Volume|Projected Sales Volume Intra-Cellular Therapies|ITCI - Market Cap to Revenue|Forward P/S Multiple Intra-Cellular Therapies Inc.

Analysis of all company metrics:Intra-Cellular Therapies, Inc. ITCI

Revenue growth for Intra-Cellular Therapies (ITCI) driven by the expanded application of its neuro-drug in depression therapy establishes a foundation for business capitalization. The price reflects the daily market value of the company's share at the close of trading, allowing investors to assess the balance between management's commercial expenditures and the actual value of assets, which clearly confirms a reversal in price action.

Analysis of competing companies